Daily Equity Reports 24 Dec 2018

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 24th DECEMBER 2018 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET PREVIOUS ! 35742.07 INDIAN EQUITY BENCHMARK :- The 30-share BSE Sensex slipped 689.60 points or 1.89 percent to 35,742.07 and the 50- 10754.00 share NSE Nifty plunged 197.70 points or 1.81 percent to ASIAN MARKET 10,754.IOC, UPL, Adani Ports, Maruti Suzuki and Indiabulls PREVIOUS Housing were top losers among Nifty50 stocks, which fell 3.5- NIKKEI 20166.19 4.5 percent.HPCL, BPCL, Coal India and NTPC were only gainers, 25753.42 up 1-2 percent.. GLOBAL FACE 2060.12 SECTORIAL INDICES ! CHANGE (%) Asian Market - Asian markets finished mixed as of the most recent closing prices. The Hang Seng gained 0.51%, while the Nikkei 225 led the Shanghai Composite lower. They fell 1.11% and 0.79% respectively. 11005.85 -1.75 -1.64 ! -2.03 U.S. Market – Dow sinks below 23,000; Nasdaq flirts with a bear market; Oil in free fall. -1.73 ! .BANK NIFTY 26869.65 -1.49 European markets - European markets are lower today with shares in France off the most. The CAC 40 is down 0.65% while London's FTSE CHANGE (%) 100 is off 0.41% and Germany's DAX is lower by 0.36%. 2.31 BPCL 0.88 0.66 0.44 TOP LOSERS CLOSE CHANGE (%) -5.44 UPL 735 -4.55 ADANIPORTS -3.71 -3.44 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE TREND STRATEGY SCRIPT CLOSE (%) 2.38 BEARISH 250 2.28 P R1 R2 11043 RESISTANCE R1-10890 R2-11040 R3 11268 TATA GLOBAL 10368 10593 10673 10818 10898 1.70 SUPPORT S1-10590 S2-10360 0.64 BOSCH CLOSE (%) -5.48 1202.70 -5.05 -4.65 TATA -4.49 TREND BULLISH NET S3 S2 S1 26773 P R1 R2 R3 26064 26575 27086 27284 (CR.) SUPPORT S1-26700 S2-26570 RESISTANCE 3955.48 BANK NIFTY DII 2905.17 NSE TOTALS ADVANCE 5 BANK NIFTY 2 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! Government set to pump Rs2,345cr into ! Indiabulls Real Estate sells stake in 2 projects in Gurugram Indiabulls Real Estate shares were up 1% in early morning trade on Friday as the company announced in a BSE press release that it has signed a deal with subsidiaries owned by The Blackstone Group L.P., a globally renowned real investor.The deal was signed so that IndiaBulls Real Estate could divest up to 50% stake in two office assets in Udyog Vihar, Gurugram, aggregating 784,000 sq.ft. Leasable office space. Air India The Government has sought Parliamentary approval to infuse Rs2, 300cr into Air India after a failed bid to sell off the airline in May. The Rs2, 300cr is an addition to the Rs27, 000cr already infused into the airline operator over a span of a decade.The cash-strapped airline has been running on taxpayer bailouts and has not made money for more than 10 years. Air India was set to be sold along with its debt of $5bn. However, the company found no takers so the Centres ambitious plans of privatizing the national airline came to a halt. Hence the Modi government took a decision to turn around the airline. estate private equity ! Sun Pharma secures USFDA approval for Elepsia Sun Pharma said that its epilepsy drug Elepsia XR has been approved by the USFDA. This is a New Drug Approval. ELEPSIA is a novel formulation of Levetiracetam 1000mg and 1500mg and is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age. The drug is developed by Sun Pharma Advanced Research Company (SPARC).Sun Pharma has in-licensed this drug from SPARC in July 2016. Elepsia XR had secured a USFDA approval in March 2015, however, due to compliance issues at Halol, Sun Pharma received a complete response letter (CRL) in September 2015. With the Halol clearance received in June 2018, this drug was expected to get a USFDA approval soon.. ! Aurobindo Pharma gets USFDA approval for Potassium Chloride ER tablets Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Potassium Chloride ExtendedRelease tablets, 8 mEq (600 mg) and 10 mEq (750 mg). Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report STOCK TO WATCH TOMORROW :- NAME OF THE STOCK : UPL DATE : 21/12/2018 SEGMENT : CASH CHART :- TYPE OF ADVICE: SELL UPL IN CASH BELOW 728 TGT 714 SL 742 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS DOWN, SHOWING MONTHLY AND WEEKLY REVERSAL AS WELL AS BREAKOUT IN DAILY CHART AND TAKING SUPPORT OF ALL MAJOR INDICATORS INCLUDING MACD,MOVING AVERAGES,VOLUME AND RSI FACTOR. OTHER REASONS IF ANY :- SUPPORT IS BREAKEN TODAY WITH HEAVY VOLUME AND SHOWING WEAKNESS IN INTRADAY CHARTS. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.com Contact no :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.